Upon depletion of CD4+ T cells, we observed in both PDAC models no significant difference in survival of mice between the depleted and non‐depleted groups, indicating that CD4+ T cells do not play a significant role in the anti‐tumor response elicited by the IL‐15 and CD40 agonist combination treatment (Figure 3e and f). This evidence concerns the gene CD40 and neoplasm.